Facebook-f Linkedin-in

News & Views

Stack of natural wooden cubes with 2024 engraved, arranged on a blue background

Scrip Asks… What Does 2024 Hold For Biopharma? – Treehill Partners CEO Ali Pashazadeh featured in Scrip’s annual outlook

Going into 2024, Treehill expects an even greater degree of scrutiny by boards and investors on the merits of deploying capital from the dwindling cash reserves to conducting clinical studies...
Read More
Coin-operated binoculars focused on snowy mountains symbolizing business outlook and future perspective

What Does 2024 Hold For Biopharma? Treehill Partners featured in Scrip

Treehill Partners featured amongst prominent KOLs in Part 2 of Scrip's 2024 biopharma outlook interview, discussing funding environment, M&A, and partnering...
Read More

Development Success in a Troubling Economic Environment – Medicine Maker Interview

Read More
Syringe, vaccine vial, and scientific report on NIH COVID-19 clinical trials for treatments and vaccines.

Interview: Treehill Partners’ Ali Pashazadeh on How to Improve Clinical Trial Design

From Ali Pashazadeh’s perspective, many trials fail because of how they are designed. And as the CEO of financial advisory firm Treehill Partners, he has a plan to solve that...
Read More
Fosun Pharma USA and Treehill Partners collaborating on capital investments in biopharma sector

Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical-stage assets, further solidifying the relationship between the two companies...
Read More